Literature DB >> 16086769

Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab.

A Jacobi, G Shuler, M Hertl.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086769     DOI: 10.1111/j.1365-2133.2005.06744.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  17 in total

1.  Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment.

Authors:  Elizabeth A Mauldin; Daniel O Morris; Dorothy C Brown; Margret L Casal
Journal:  Vet Dermatol       Date:  2010-04-01       Impact factor: 1.589

Review 2.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 3.  Seeking approval: present and future therapies for pemphigus vulgaris.

Authors:  Xuming Mao; Aimee S Payne
Journal:  Curr Opin Investig Drugs       Date:  2008-05

4.  A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.

Authors:  R P Hall; J Fairley; D Woodley; V P Werth; D Hannah; R D Streilein; J McKillip; J Okawa; M Rose; L L Keyes-Elstein; A Pinckney; A Overington; J Wedgwood; L Ding; B Welch
Journal:  Br J Dermatol       Date:  2015-02-05       Impact factor: 9.302

Review 5.  The continuing evolution of targeted therapy for inflammatory skin disease.

Authors:  C Schlapbach; A A Navarini
Journal:  Semin Immunopathol       Date:  2015-09-30       Impact factor: 9.623

Review 6.  [Off-label use of infliximab].

Authors:  M Onder; C Salavastru; K Fritz
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

7.  Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.

Authors:  Misa Hirose; Anika Kasprick; Foteini Beltsiou; Katharina Dieckhoff Schulze; Franziska Sophine Schulze; Unni Kjsrl Samavedam; Jennifer E Hundt; Hendri H Pas; Marcel F Jonkman; Enno Schmidt; Kathrin Kalies; Detlef Zillikens; Ralf J Ludwig; Katja Bieber
Journal:  Mol Med       Date:  2016-12-20       Impact factor: 6.354

8.  A hypothesis concerning a potential involvement of ceramide in apoptosis and acantholysis induced by pemphigus autoantibodies.

Authors:  Wendy B Bollag
Journal:  Dermatol Res Pract       Date:  2010-05-18

Review 9.  Novel therapies for pemphigus vulgaris: an overview.

Authors:  Oliver A Perez; Timothy Patton
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 10.  Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.

Authors:  Francesco Caso; Luca Iaccarino; Silvano Bettio; Francesca Ometto; Luisa Costa; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.